Table 1 Summary of studies and treatment arms included in the mixed treatment comparison analysis (primary analysis)

Endpoint reported

Treatments

Change from baseline in FEV₁

28 (85)

Placebo

14 (13)

Annual rate of moderate/severe exacerbations

15 (45)

FF/VI 50/25 QD

3 (3)

Change from baseline in total SGRQ

20 (61)

FF/VI 100/25 QD

7 (7)

Exacerbation history

FF/VI 200/25 QD

3 (3)

At least 1

14 (42)

FF 100 QD

2 (2)

At least 2

3 (9)

FF 200 QD

1 (1)

Not reported

16 (48)

VI 25 QD

4 (4)

% Predicted FEV₁

FP/SAL 250/50 BID

8 (8)

<50%

13 (39)

FP/SAL 500/50 BID

14 (13)

50%–70%

16 (48)

FP/SAL 500/50 BID + TIO18 QD

1 (1)

>70%

4 (12)

SAL 50 BID

10 (10)

Mean age reported

63.79

SAL 50 BID + theophylline

1 (1)

Mean proportion male

0.73

FP 250 BID

1 (1)

Mean proportion current smokers

0.46

FP 500 BID

3 (3)

FP 500 BID + TIO 18 QD

1 (1)

BUD/FORM 160/9 BID

3 (3)

BUD/FORM 400/12 BID

9 (9)

BUD 160 BID

1 (1)

BUD 320 BID

3 (3)

FORM 9 BID

8 (8)

MMF 400 BID

1 (1)

MMF/FORM 200/10 BID

1 (1)

MMF/FORM 400/10 BID

1 (1)

TIO 18 QD

3 (3)

BDP(extra fine)/FORM 200/12 BID

1 (1)